Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies.

ABSTRACT:

Background

The prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world, yet the total economic burden has not been quantified. Improved understanding of costs and the impact of treatment strategies will provide for better allocation of resources to reduce HCV disease and economic burden.

Aim

A modelling approach was used to quantify the current HCV-infected population, future disease progression and associated costs in Egypt.

Methods

Direct healthcare costs were calculated from a nationally representative hospital and a disability adjusted life year (DALY) template was used with monetary value assigned to lost life years. Three scenarios were considered: (i) Historical treatment scenario: 50% SVR; 65,000 treated annually, (ii) Current trea

SUBMITTER: Estes C 

PROVIDER: S-EPMC5034818 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature